A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, ...

Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

For decades, doctors have worked to protect people from Streptococcus pneumoniae, a bacterium responsible for pneumonia, ...

In a recent multicenter prospective study conducted at three hospitals in Tennessee and Georgia, including Vanderbilt ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

Streptococcus pneumoniae attacks compromised or undeveloped immune systems, making the elderly and children especially vulnerable. It is blamed for over 22,000 deaths, 400,000 hospitalizations and ...

New research has uncovered exactly how the bacterium Streptococcus pneumoniae has become resistant to the antibiotic penicillin. The same research could also open up MRSA to attack by penicillin ...

Streptococcus pneumoniae binds to host GAPDH on dying lung epithelial cells worsening secondary infection following influenza. Cell Reports, 2021; 35 (11): 109267 DOI: 10.1016/j.celrep.2021.109267 ...

Thus, our finding of PspA's role in adherence substantially advances our knowledge on the interactions of S. pneumoniae with its host." Reference: Park S-S, Gonzalez-Juarbe N, Riegler AN, et al.